關於 cookie 的說明

本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。

Global Business NewsGlobal Business News

目前Global Business News文章數, 共 20913 篇 ,以下為 289 - 312 篇 訂閱此列表,掌握最新動態
Mabwell Releases Preclinical Study Results of Multiple Innovative Drugs Released at the 2024 AACR Annual Meeting

SHANGHAI, April 16, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, presented the preclinical research findings of three potential novel drug candidates in poster format at the American Association for Cancer Research (AACR) Annual Meeting, held from April 5 to 10, 2024. Poster Presentation 1.  Disrupting IL-11/IL-11R signaling by an efficacious anti-IL-11 antibody 9MW3811 enhances T cell tumor infiltration and synergizes with anti-PD-1 therapies in vivo Synopsis No.: 2365 The reported 9MW3811 is a high-affinity humanized neutralizing antibody against IL-11 independently developed by Mabwell, and has IND applications approved in China, the United States, and Australia, and its phase I clinical trials are ongoing in Australia and China. As an important inflammation factor, IL-11 plays a significant role in the development and progression of fibrosis and tumor. Studies have shown that high expression of IL-11 is associated with the prognosis of various tumors such as lung cancer, hepatic cancer, and colorectal cancer. IL-11 not only promotes the growth of tumor cells through the STAT3 pathway but also has a significant impact on immune cells in the tumor microenvironment. 9MW3811 effectively blocks the formation of the IL-11/IL-11Ra/gp130 ternary complex by binding to IL-11, thereby inhibiting the activation of downstream signaling pathways. 9MW3811 has shown good anti-tumor therapeutic effects in multiple preclinical pharmacodynamic models, especially when used in combination with anti-PD-1 antibodies, it significantly promotes lymphocytic infiltration of CD8+ T cells, improves the T cell exhaustion caused by anti-PD-1 antibodies, upregulates the secretion of cytotoxic cytokines, thus exhibiting better combined anti-tumor effects.   2.  2MW4991, a novel ADCC-enhanced integrin αvβ8 blocker, exhibits high anti-tumor potency and was well tolerated in cynomolgus monkeys Synopsis No.: 6349 The reported 2MW4991 is a high-specificity and high-affinity ADCC-enhanced antibody targeting integrin αvβ8. Integrin αvβ8 is an important activator of TGF-β, and specifically regulates the activity of TGF-β in immune cells. Studies have found that integrin αvβ8 is highly expressed in various tumors, and blocking αvβ8 can completely inhibit the release of TGF-β. 2MW4991 can completely block the release of TGF-β mediated by αvβ8, showing strong anti-tumor activity in various pharmacodynamic models such as CT26 and EMT6, and significantly promotes immune cell infiltration in tumors, greatly increasing the sensitivity of immune-excluded tumors to PD1 inhibitors. 2MW4991 has a significant synergistic effect when used in combination with PD1. The studies conducted in non-primate models have shown that 2MW4991 has good safety and metabolic profiles. 3.  2MW4691, a novel CCR8/CTLA-4 bispecific antibody, displays potent anti-tumor efficacy by specifically depleting tumor-infiltrating Tregs and blocking CTLA-4 signaling on CD8+ T cells Synopsis No.: 6350 The reported 2MW4691 is an ADCC-enhanced bispecific antibody targeting CCR8/CTLA-4. Targeting CTLA-4 has a strong anti-tumor effect, but its clinical application is limited due to strong side effects. CCR8 is a specific marker of tumor-infiltrating Tregs, and is almost not expressed in other immune cells and peripheral Tregs. Single-cell sequencing analysis of Treg cells infiltrating various tumors found that CCR8 is expressed in a small subset of Treg cells infiltrating tumors, and CTLA-4 is widely expressed in Treg cells and CD8+ T cells. 2MW4691 retains high affinity targeting CCR8 and attenuated CTLA-4-binding and -blocking activity, specifically eliminating Treg cells infiltrating tumors. Due to the lower CTLA-4 expression in the peripheral tissues, 2MW4691 only blocks the immunosuppression mediated by CTLA-4 signaling on peripheral CD8+ T cells. 2MW4691 demonstrates strong anti-tumor activity in preclinical CCR8 single transgenic animal models, CTLA-4 single transgenic animal models, and double transgenic animal models, and has shown good metabolic activity and safety in primate animals. About Mabwell Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with the entire value chain of the pharmaceutical industry. We provide more effective and accessible therapy and innovative medicines to fulfill global medical needs. Since 2017, an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation was established. Mabwell has 14 pipeline products in different stages based on a world-class and state-of-the-art R&D engine, including 10 novel drug candidates and 4 biosimilars. We focus on the therapeutic areas of oncology, auto-immune diseases, metabolic disorders, ophthalmologic diseases and infectious diseases, etc. Of these, 3 products have been approved and commercialized, 1 product has been filed for MA approval, 3 products are in pivotal trials. We have also undertaken 1 national major scientific and technological special project for "Significant New Drugs Development", 2 projects for National Key R&D Programmes, and multiple provincial and municipal science and technological innovation projects. Mabwell's Taizhou factory possesses robust in-house manufacturing capability compliant with international GMP standards regulated by the NMPA, FDA and EMA, and has passed the EU QP Audit. The large-scale manufacturing base located in Shanghai is under construction. Our mission is "Explore Life, Benefit Health" and our vision is "Innovation, from ideas to reality". For more information, please visit www.mabwell.com/en. Forward-Looking Statements This press release contains forward-looking statements including, but not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those relating to the Company's product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. "Forward-looking statements" are statements that are not historical facts and involve a number of risks and uncertainties, which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would," and similar expressions and the negatives of those terms. Forward-looking statements are based on the Company's current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company's control, including, but not limited to: environment; politic; economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the potential impact of COVID-19; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties deteriorate, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results. The Company cautions all the persons not to place undue reliance on any such forward-looking statements, which speaks only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions, figures and assumptions in this press release are applicable to this statement.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 161 加入收藏 :
GAC TECH DAY 2024: Groundbreaking Innovations Redefine Automotive Excellence

GUANGZHOU, China, April 16, 2024 /PRNewswire/ -- On April 12, GAC TECH DAY 2024 took center stage at the GAC Research Institute in Guangzhou, China, under the theme "See the World with New Vision." The conference was attended by approximately 260 foreign and domestic media outlets and distinguished guests, including relevant Guangdong Province and Guangzhou City leaders, Zeng Qinghong, Chairman of GAC Group, and Feng Xingya, President of GAC Group. GAC TECH DAY 2024: Groundbreaking Innovations Redefine Automotive Excellence On the day, GAC, a trailblazer in automotive advancements, unveiled several groundbreaking technologies set to revolutionize the driving experience. First, the Garcia Intelligent Driving System, a pioneering pure vision-based intelligent driving solution devoid of maps, promises a seamless and immersive driving experience. Unlike traditional systems reliant on high-precision maps and LiDAR, Garcia leverages visual sensors and AI algorithms to perceive the world with human-like precision. With three leading capabilities in visual recognition, Garcia offers unparalleled accuracy and reliability in complex traffic scenarios. GAC also announced key breakthroughs in its all-solid-state power battery technology, setting a new standard for energy density, safety, and capacity. The innovative battery promises extended ranges exceeding 1000km and enhanced safety under extreme conditions.  Both innovations are set for mass production and deployment by 2026. In addition to technological breakthroughs, GAC showcased a range of advanced technologies and user-centric products, including electromagnetic suspension, skateboard chassis, and GOVE, the company's first eVTOL mobility solution that has already completed its maiden flight this March. GAC's new iGLCA intelligent light commercial vehicle segment—MIRACO Motor—also made its official debut at GAC TECH DAY 2024 with the release of its flagship model "MiraLounge". Primarily designed for passenger transport services, the vehicle allows for the separation of cabin and driving compartment to achieve a multi-model derivation through "MiraBoard 2.0" technology. The vehicle supports L2 to L4 level intelligent driving and is scheduled to hit the market in the fourth quarter of 2024.  The event also marked the launch of the Welfare Edition of E9, GAC's luxury PHEV MPV. The new version of the 7-seater caters to users with mobility challenges with its unique detachable electric seat. GAC's relentless pursuit of innovation underscores its vision to reshape the automotive landscape and drive sustainable growth. With a focus on technology-driven development, GAC aims to continue pushing the boundaries of automotive excellence, setting new benchmarks for the industry.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 180 加入收藏 :
Scientific Innovation Transforms Cangzhou's Saline-Alkali Fields into Fertile Land

CANGZHOU, China, April 16, 2024 /PRNewswire/ --  A once-barren field under saline-alkali stress is now teeming with life in Cangzhou in north China's Hebei province, thanks to measures to prioritize the comprehensive use of saline-alkali land, leverage the key role of scientific and technological innovation, expand the cultivation area of suitable crops and develop the intensive processing of farm products, according to Cangzhou municipal government. This project holds significant importance in enhancing the comprehensive utilization capacity of saline-alkali land, and improving the economic and social benefits of dryland alkaline wheat production. The China National Standardization Management Committee officially approved Cangzhou the National Dryland Alkaline Wheat Agricultural Standardization Regional Service and Promotion Platform project with construction period of three years, the first of its kind nationwide, which covers the dryland alkaline winter wheat planting area in the low-lying plains around the Bohai Sea. The unique natural conditions in Cangzhou have laid the foundation for the development of dryland alkaline wheat agriculture. Cangzhou experiences dry and less rainy winters and springs, with high levels of soil salinization and alkalization. Ordinary wheat struggles to grow in such an environment, but dryland alkaline wheat thrives. The cultivated area of saline-alkali land in Cangzhou is 4.1 million mu accounting for over 70 percent of the total saline-alkali land area in Hebei Province, indicating significant potential for comprehensive management and utilization. Through repeated selection and improvement by local agricultural technicians, the yield of dryland alkaline wheat in Cangzhou has been increasing year by year. In 2023, the grain planting area in Cangzhou City reached 13.546 million mu, with a total output of 4.67 million tons, successfully completing the provincial grain production tasks. Among them, 1.547 million mu were planted with dryland alkaline wheat, exceeding the target of 1.5 million mu. The saline-alkali land, which used to yield nothing for nine out of ten years, has not only become fertile farmland but is also growing into a major granary in the Bohai Bay region. Of particular note is that the grains of dryland alkaline wheat in Cangzhou are full and translucent, rich in calcium, potassium, iron, zinc, and other trace elements, with a protein content ranging from 13 percent to 16 percent (national standard is 12.2 percent). Once completed, the project will establish core demonstration sites covering an area of over 1333 hectares, radiating and driving the standardized planting area of dryland alkaline wheat in saline-alkali coastal areas around the Bohai Sea, including Hebei, Shandong, and Tianjin, to reach 33,300 hectares.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 150 加入收藏 :
Gatorade Named Official Sports Drink of Rob McElhenney and Ryan Reynolds' Wrexham AFC

The iconic sports drink brand fuels Wrexham's Men's and Women's Teams CHICAGO and WREXHAM, Wales, April 16, 2024 /PRNewswire/ -- Today, Gatorade announced its official sports drink partnership with the Wrexham Association Football Club, fueling the club's Men's and Women's teams. The deal comes three days after the club's second consecutive promotion, up to League One, and enables Gatorade and its science-backed products and innovations to support Wrexham in the team's aspirations to reach the Premier League. Gatorade announces an official partnership with Wrexham AFC. As part of the partnership, fans will see Gatorade, the global leader in sports fuel, on the sidelines of all Wrexham AFC games and the integration of Gatorade products within FX's "Welcome to Wrexham" show this upcoming season premiering Thursday, May 2, 2024. "We are incredibly pleased and humbled to welcome Gatorade as an official partner of Wrexham Association Football Club. We are officially pretty darn official! Our decision early on to have Aviation Gin in those water bottles was reckless and shortsighted. Luckily, our team has forgiven us and has gone on to perform admirably, in part thanks to Gatorade! We look forward to a few more Gatorade dunks in the years to come," said club co-chairmen Rob McElhenney and Ryan Reynolds.  Gatorade is the world's most researched sports drink, offering a breadth of hydration options to fuel Wrexham AFC's athletes from training to gameday and post-win celebrations. Wrexham players will also have access to the resources offered by the Gatorade Sports Science Institute (GSSI), which is committed to helping athletes optimize their health and performance through research, innovation, education and service in hydration and nutrition science. As part of the team's upcoming work with GSSI, Wrexham players will participate in sweat testing, where sweat patterns are analyzed by GSSI to inform the development of custom fuel plans, so athletes understand what they're losing in sweat and how to hydrate effectively. Future plans for the partnership also include co-branded merchandise such as exclusive Wrexham Gx bottles and towels. "We at Gatorade are thrilled to welcome Wrexham AFC, who has captivated global soccer and pop culture fans alike, as our newest partner," said Michael Del Pozzo, President and General Manager, Gatorade. "From the natural integration into 'Welcome to Wrexham', to leveraging our products and GSSI's capabilities to help fuel the teams, this partnership is a first of its kind for Gatorade, leveraging the powerful intersection of sports and entertainment to reach new audiences around the globe." This news comes in advance of the club's tour of the United States this summer, where the two Gatorade-fueled teams will face off against some of football's best clubs and players. As part of the Wrex Coast Tour, the Men's club will be returning to the United States for the second year in a row for three friendly matches and the Women's club will be making their first visit to the U.S. Dates of the 2024 Wrex Coast Tour will be announced soon. Follow @Wrexham_AFC, @Gatorade and visit www.wrexhamafc.co.uk for more info. About The Gatorade PortfolioThe Gatorade Portfolio, a division of PepsiCo (NASDAQ: PEP), is a connected performance and wellness ecosystem built to fuel all athletes and exercisers. Bringing together Gatorade, Fast Twitch, Propel, Evolve and Muscle Milk, the Gatorade Portfolio is the most complete offering in the category today, with a broad range of personalized solutions at every stage of the athlete journey. This integrated system of brands is built on Gatorade's 57-year history of studying athletes and is fueling the future of athletic performance and wellness by delivering solutions across hydration, protein, energy and all-day nutrition to fuel consumers, no matter how or why they sweat. For more information and a full list of product offerings, please visit www.gatorade.com. AboutPepsiCoPepsiCo products are enjoyed by consumers more than one billion times a day in more than 200 countries and territories around the world. PepsiCo generated more than $91 billion in net revenue in 2023, driven by a complementary beverage and convenient foods portfolio that includes Lay's, Doritos, Cheetos, Gatorade, Pepsi-Cola, Mountain Dew, Quaker, and SodaStream. PepsiCo's product portfolio includes a wide range of enjoyable foods and beverages, including many iconic brands that generate more than $1 billion each in estimated annual retail sales. Guiding PepsiCo is our vision to Be the Global Leader in Beverages and Convenient Foods by Winning with pep+ (PepsiCo Positive). pep+ is our strategic end-to-end transformation that puts sustainability and human capital at the center of how we will create value and growth by operating within planetary boundaries and inspiring positive change for planet and people. For more information, visit www.pepsico.com, and follow on X (Twitter), Instagram, Facebook, and LinkedIn @PepsiCo. About Wrexham AFCWrexham Association Football Club is based in Wrexham, North Wales, and competes in League Two, the fourth tier of the English football league pyramid. For the 2024/25 season, Wrexham will compete in League One – the third tier – after securing a second consecutive promotion.  Formed in 1864, they are the oldest club in Wales and the third oldest professional team in the world. Wrexham has won the Welsh Cup a record 23 times and beaten some of the biggest clubs in the game in the English FA Cup and UEFA European Cup Winners Cup. The STōK Cae Ras, home to Wrexham AFC, is the world's oldest international stadium that still continues to host international games. Wrexham AFC is owned by Rob McElhenney and Ryan Reynolds. The goal of the new owners is to grow the team and establish Wrexham AFC as a Premier League club in front of increased attendances, and in an improved stadium, while making a positive difference to the wider community in Wrexham This goal is being pursued through four guiding principles: i) to protect the heritage of Wrexham AFC; ii) to reinforce the values of the community; iii) to use Rob and Ryan's resources to grow the exposure of the club at home and abroad; and iv) to create a winning culture. For more information, please visit wrexhamafc.co.uk. CONTACT: Joe Giordano, joe.giordano@fleishmanhillard.com 

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 80 加入收藏 :
SS&C Blue Prism Intelligent Automation Customers Unlocked $53.4M in Value

The Total Economic Impact Study examines IA benefits on five SS&C Blue Prism customers and 166 global respondents WINDSOR, Conn., April 16, 2024 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the findings of The Total Economic Impact™ (TEI) of SS&C Blue Prism1, a 2024 study conducted by Forrester Consulting. SS&C Blue Prism commissioned the study to examine the potential Total Economic Impact™ enterprises may realize by deploying an Intelligent Automation Platform, and evaluate the full potential financial impact of adopting SS&C Blue Prism Intelligent Automation. The study found a composite organization representative of interviewed customers using SS&C Blue Prism technologies saw a return on investment figure of 330% over three years, representing a net present value of $53.4 million. "[O]ver the last five years, IA has moved from addressing mainly operational challenges to more strategic challenges," stated the TEI study. "IA is also increasingly driven by management and leadership, rather than the IT or technology department and, while today automation management is coordinated across the organization, it used to be siloed." The study reveals an overall revenue growth of 5.4% CAGR for the composite customer, an 8% increase in productivity, and 7.3% increased employee retention, along with a payback time of less than six months.2 "The Forrester study's findings confirm SS&C Blue Prism's intelligent automation's ability to drive business growth, enhance productivity, and improve employee retention," said Bill Stone, Chairman and CEO of SS&C Blue Prism. "SS&C Blue Prism's end-to-end automation and orchestration enable customers to drive value and efficiently achieve transformative results." Among 166 respondents Forrester surveyed, 60% revealed speed, productivity, accuracy and auditability improvements as a top benefit, while 65% had extended value across more end-to-end processes from a combined automation and orchestration solution. Key quantified benefits over three years for the composite customer include: Business growth worth $50.3 million  $12.7 million in improved productivity  $2.4 million compliance cost avoidance  $4.2 million in improved employee experience and retention More than 2,800 customers worldwide run their operations on SS&C Blue Prism, digitizing operations across financial services, insurance, health and pharma, banking, and more. Download the study today. Notes 1 Total Economic Impact is a methodology developed by Forrester Research that enhances a company's technology decision-making processes and assists vendors in communicating the value proposition of their products and services to clients. The TEI methodology helps companies demonstrate, justify, and realize the tangible value of IT initiatives to both senior management and other key business stakeholders.2 By investing in intelligent automation the study found a received revenue growth of 73% of overall NPV benefit and 5.4% compound annual growth rate (CAGR) over the previous three years for a composite customer. About SS&C Technologies SS&C is a global provider of services and software for the financial services and healthcare industries. Founded in 1986, SS&C is headquartered in Windsor, Connecticut, and has offices around the world. Some 20,000 financial services and healthcare organizations, from the world's largest companies to small and mid-market firms, rely on SS&C for expertise, scale and technology. Additional information about SS&C (Nasdaq: SSNC) is available at www.ssctech.com. Follow SS&C on Twitter, LinkedIn and Facebook.  

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 88 加入收藏 :
IMG Sends Employees on Fifth Corporate Service Trip with School the World

INDIANAPOLIS, April 16, 2024 /PRNewswire/ -- IMG (International Medical Group), an award-winning global insurance benefits and assistance services company, is excited to highlight the success of its 2024 corporate service trip with School the World, a nonprofit organization focused on providing access to quality education in Central America. As part of its sponsorship with School the World, IMG sent seven employees on a week-long service trip to Northern Panama to assist in building a new school and playground. "It was an honor to be part of IMG's team for this year's corporate service trip with School the World," said Grant Hayes, IMG Director of International Sales – Travel. "My colleagues and I were able to work together to make a lasting impact in the Panama community where we served, and this was a life-changing experience we will truly never forget. Thank you to IMG for allowing us to have this incredible opportunity." The service trip participants assisted in mixing and pouring cement for the school's flooring and sidewalks and also helped paint the school and its playground equipment. The finished project was dedicated with a ribbon-cutting ceremony at the end of the week. Additionally, the team was able to connect with the community by playing with students at recess and visiting local homes throughout the week. "We are so grateful to IMG and its employees for repeatedly participating in our corporate service trips year after year," said Kate Curran, Founder and CEO of School the World. "At School the World, we believe access to education is essential to creating change, and the positive change we create in these poverty-stricken communities wouldn't be possible without the support of corporate partners like IMG." IMG selected seven employees to go on the trip based on applications submitted via written essay or video. Each applicant responded to the following question: "How will this experience help you better understand what it's like to 'Be There' for our customers and clients?" "IMG's purpose is to be there to protect and enhance the well-being of our customers, and this trip allows our employees to gain first-hand experience and insight into what it's like visiting a remote area far from home," said Amanda Winkle, IMG Chief Operating Officer. "We're proud to have sponsored School the World for several years, and we're excited that our employees were able to be part of School the World's first corporate service project in Panama." The 2024 trip marks the fifth time that IMG has participated in a School the World corporate service trip. For more information about School the World, visit https://schooltheworld.org/. About IMG® (International Medical Group®) IMG® (International Medical Group®), a SiriusPoint company, is an award-winning global insurance benefits and assistance services company that has served millions of members worldwide since its founding in 1990. The preeminent provider of travel and health safety solutions, IMG offers a wide range of insurance programs, including international private medical insurance, travel medical insurance, and travel insurance, as well as enterprise services, including insurance administrative services and 24/7 emergency medical, security, and travel assistance. IMG's world-class services, combined with an extensive product portfolio, provide Global Peace of Mind® for travelers, students, missionaries, marine crews, and other individuals or groups traveling, working, or living away from home. For more information, please visit www.imglobal.com. About School the World Our mission is to solve extreme poverty through the power of education. We believe that by working together we can create a world where every child has the quality education they deserve. That is why we work both on the ground in poverty-stricken communities who have little to no access to education, as well as right here in the U.S., providing students, families, and companies the opportunity to create change. Our strategy is to work at the grassroots level, organizing communities around education from early childhood through adolescence. Our Service Program amplifies our impact at home & abroad. Everyone, working together, towards making our world a more just place. Learn more at www.schooltheworld.org.  

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 68 加入收藏 :
首 頁 我的收藏 搜 尋 新聞發佈